Swiss drugs giant Roche is rejoining the Association of the British Pharmaceutical Industry after cutting ties with the trade body seven years ago.
In June 2009 the firm announced that it would not be renewing its ABPI membership, citing a need to review its relationship with the organisation.
The move came after Roche had its membership suspended for six months in connection with “serious breaches” of the Association’s Code of Practice, relating to the inappropriate sale of large quantities of its weight-loss drug Xenical (orlistat) to an operator of private diet clinics.
Now, commenting on the firm’s renewed membership, Richard Erwin, General Manager of Roche Products, said: “Our industry can be subject to significant environmental shifts and we recognise how important it will be to collaborate with other companies, the NHS and healthcare professionals to ensure that UK patients can get access to world leading healthcare.”
“We are absolutely delighted to welcome Roche to the ABPI,” said its chief executive Mike Thompson. “This is an exciting and critical time for the UK pharmaceutical industry as we face up to a number of challenges, in particular addressing life outside of the European Union.
“It’s important that the ABPI can provide a coherent and aligned voice for our industry which represents the views of companies large and small.”
The trade association said it now represents nine out of 10 of the world’s largest pharmaceutical companies.
By Selina McKee
Source: Pharma Times
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.